174 related articles for article (PubMed ID: 34285910)
1. Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.
Che X; Zhan J; Zhao F; Zhong Z; Chen M; Han R; Wang Y
Biomed Res Int; 2021; 2021():4340950. PubMed ID: 34285910
[TBL] [Abstract][Full Text] [Related]
2. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway.
Cao R; Meng Z; Liu T; Wang G; Qian G; Cao T; Guan X; Dan H; Xiao Y; Wang X
Oncotarget; 2016 Nov; 7(45):72941-72960. PubMed ID: 27662662
[TBL] [Abstract][Full Text] [Related]
3. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways.
Jiang JH; Pi J; Jin H; Cai JY
J Cell Biochem; 2019 Mar; 120(3):3736-3746. PubMed ID: 30229997
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of TRPM7 prevents tumor growth, migration, and invasion through the Src, Akt, and JNK pathway in bladder cancer.
Lee EH; Chun SY; Kim B; Yoon BH; Lee JN; Kim BS; Yoo ES; Lee S; Song PH; Kwon TG; Ha YS
BMC Urol; 2020 Sep; 20(1):145. PubMed ID: 32907556
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion.
Chen WL; Barszczyk A; Turlova E; Deurloo M; Liu B; Yang BB; Rutka JT; Feng ZP; Sun HS
Oncotarget; 2015 Jun; 6(18):16321-40. PubMed ID: 25965832
[TBL] [Abstract][Full Text] [Related]
6. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway.
Yang J; Ren X; Zhang L; Li Y; Cheng B; Xia J
Biomed Pharmacother; 2018 Apr; 100():226-232. PubMed ID: 29432993
[TBL] [Abstract][Full Text] [Related]
7. Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects.
Yang J; Jiang H; Wang C; Yang B; Zhao L; Hu D; Qiu G; Dong X; Xiao B
Biomed Pharmacother; 2015 May; 72():125-34. PubMed ID: 26054686
[TBL] [Abstract][Full Text] [Related]
8. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway.
Liu H; Qian C; Shen Z
Tumour Biol; 2014 Sep; 35(9):9139-46. PubMed ID: 24916572
[TBL] [Abstract][Full Text] [Related]
10. Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.
Chen WL; Turlova E; Sun CL; Kim JS; Huang S; Zhong X; Guan YY; Wang GL; Rutka JT; Feng ZP; Sun HS
Mar Drugs; 2015 Apr; 13(4):2505-25. PubMed ID: 25913706
[TBL] [Abstract][Full Text] [Related]
11. Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma
Song M; Liu X; Liu K; Zhao R; Huang H; Shi Y; Zhang M; Zhou S; Xie H; Chen H; Li Y; Zheng Y; Wu Q; Liu F; Li E; Bode AM; Dong Z; Lee MH
Mol Cancer Ther; 2018 Jul; 17(7):1540-1553. PubMed ID: 29695636
[TBL] [Abstract][Full Text] [Related]
12. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway.
Bao R; Shu Y; Wu X; Weng H; Ding Q; Cao Y; Li M; Mu J; Wu W; Ding Q; Tan Z; Liu T; Jiang L; Hu Y; Gu J; Liu Y
BMC Cancer; 2014 Mar; 14():217. PubMed ID: 24655726
[TBL] [Abstract][Full Text] [Related]
13. Oridonin inhibits hypoxia-induced epithelial-mesenchymal transition and cell migration by the hypoxia-inducible factor-1α/matrix metallopeptidase-9 signal pathway in gallbladder cancer.
Chen K; Ye J; Qi L; Liao Y; Li R; Song S; Zhou C; Feng R; Zhai W
Anticancer Drugs; 2019 Oct; 30(9):925-932. PubMed ID: 31517732
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TRPM7 with waixenicin A reduces glioblastoma cellular functions.
Wong R; Gong H; Alanazi R; Bondoc A; Luck A; Sabha N; Horgen FD; Fleig A; Rutka JT; Feng ZP; Sun HS
Cell Calcium; 2020 Dec; 92():102307. PubMed ID: 33080445
[TBL] [Abstract][Full Text] [Related]
15. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
16. Oridonin induces growth inhibition and apoptosis in human gastric carcinoma cells by enhancement of p53 expression and function.
Bi E; Liu D; Li Y; Mao X; Wang A; Wang J
Braz J Med Biol Res; 2018 Nov; 51(12):e7599. PubMed ID: 30462771
[TBL] [Abstract][Full Text] [Related]
17. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
Wang YY; Lv YF; Lu L; Cai L
Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
[TBL] [Abstract][Full Text] [Related]
18. Semaphorin 4D promotes the proliferation and metastasis of bladder cancer by activating the PI3K/AKT pathway.
Lu JJ; Su YW; Wang CJ; Li DF; Zhou L
Tumori; 2019 Jun; 105(3):231-242. PubMed ID: 30674231
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
20. Silencing TRPM7 in mouse cortical astrocytes impairs cell proliferation and migration via ERK and JNK signaling pathways.
Zeng Z; Leng T; Feng X; Sun H; Inoue K; Zhu L; Xiong ZG
PLoS One; 2015; 10(3):e0119912. PubMed ID: 25799367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
